Addressing the Burden of Cardiovascular Comorbidities in Narcolepsy: Strategies and Perspectives to Optimize Treatment and Patient Outcomes
Addressing the Burden of Cardiovascular Comorbidities in Narcolepsy: Strategies and Perspectives to Optimize Treatment and Patient Outcomes is organized by Healio.
Release Date: 8/11/2023
Expiration Date: 8/11/2024
Activity Description
Several cardiometabolic comorbidities are common in patients with narcolepsy. Often these disorders are overlooked, but they have important implications in the management of this condition. Some medications used to treat symptoms of narcolepsy may have potentially negative effects on cardiovascular health, including in patients who are sensitive to sodium, such as those with hypertension or other cardiovascular risk factors.
This activity overviews the links between cardiometabolic risk and narcolepsy, individualization of therapy for narcolepsy patients with cardiovascular risk, as well as narcolepsy treatment options and recent advances in pharmacotherapy for these patients. The information is presented in an interactive format, which contains a mix of high-impact visuals, infographics, expert faculty videos, as well as resources, and suggested readings, all organized into different segments to facilitate learning.
Learning Objective
After completing this activity, the participant should be better able to:
• Recognize that cardiovascular risk factors are common in patients with narcolepsy.
• Describe the pathophysiological connections between narcolepsy and increased cardiovascular risk.
• Explain the rationale and evidence behind the increased risk for major adverse cardiovascular events with commonly used narcolepsy agents.
• Summarize recent updates with new and emerging narcolepsy treatments.
